Gossamer Bio holder reports 1.7% stake after sales
Gossamer Bio, Inc. received an amended Schedule 13D from New Enterprise Associates–affiliated entities led by Growth Equity Opportunities 18 VGE, LLC, updating their ownership in the company’s common stock.
Rhea-AI Filing Summary
Gossamer Bio, Inc. received an amended Schedule 13D from New Enterprise Associates–affiliated entities led by Growth Equity Opportunities 18 VGE, LLC, updating their ownership in the company’s common stock.
On February 23, 2026, GEO completed open‑market public sales totaling 17,093,034 shares of Gossamer Bio common stock at a weighted average price of $0.3906 per share, with trade prices ranging from $0.3320 to $0.6363 per share.
After these transactions, as of February 23, 2026 GEO is the record owner of 1,000,000 shares and may be deemed to beneficially hold an additional 3,065,134 shares underlying GEO warrants, for total GEO‑related beneficial ownership of 4,065,134 shares, or 1.7% of Gossamer Bio’s outstanding common stock. That percentage is based on 234,521,381 shares, including 231,456,247 shares outstanding as of October 31, 2025 plus the GEO warrants. Voting and dispositive power over these shares is reported as shared among GEO, affiliated NEA entities, and several individual managers, each of whom disclaims beneficial ownership beyond shares held of record.
Positive
- None.
Negative
- Large stockholder executed significant open‑market sales, with GEO selling 17,093,034 Gossamer Bio shares at a weighted average price of $0.3906 per share, leaving the group with a reported 1.7% beneficial stake.
Insights
Large venture holder reports sizable open‑market sales and a reduced 1.7% position.
Affiliates of New Enterprise Associates, through Growth Equity Opportunities 18 VGE, LLC and related entities, disclosed that GEO sold 17,093,034 Gossamer Bio shares in open‑market transactions on February 23, 2026. The weighted average sale price was $0.3906 per share, with a broad intraday range.
Following these sales, the group reports beneficial ownership of 4,065,134 shares, including 3,065,134 underlying GEO warrants, representing 1.7% of the company’s common stock based on 234,521,381 shares. All voting and dispositive power is characterized as shared among GEO, several NEA funds, and multiple managers, who each disclaim ownership beyond shares held of record.
For investors, this filing highlights that a major growth‑equity sponsor has executed substantial open‑market sales and now holds a relatively small single‑digit percentage stake. Future company filings and ownership reports may further clarify any additional changes in this holder’s position.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the NEA Schedule 13D/A filing say about Gossamer Bio (GOSS) ownership?
What Gossamer Bio (GOSS) holdings does GEO report after the sales?
How was the 1.7% ownership in Gossamer Bio (GOSS) calculated in the 13D/A?
Who are the reporting persons in the Gossamer Bio (GOSS) Schedule 13D/A amendment?
Do the NEA reporting persons claim full beneficial ownership of all Gossamer Bio (GOSS) shares?
AI-generated analysis. How Rhea-AI works. Not financial advice.